Actio Biosciences

Biotech · Pharmaceuticals · Rare Disease

Acquisition

Jazz Pharmaceuticals to buy Actio Biosciences for $820M upfront

The deal targets an ultra-rare epilepsy with zero approved treatments, a niche too small for most drugmakers to chase.

• Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront, plus up to $500 million in approval and sales milestones, in a deal expected to close by Q4 2026.
• San Diego-based Actio develops ABS-1230, a first-in-class oral small-molecule inhibitor of the KCNT1 ion channel, targeting a rare genetic epilepsy with no FDA-approved therapies.
• ABS-1230 has shown meaningful seizure reductions in early proof-of-concept data and is now in the Phase 1b/2a KYRON trial, designed to support a future FDA application.
• As part of the deal, Actio will spin out most of its pipeline, staff, and management into a new, existing-investor-funded company focused on genetic rare neurological diseases; Jazz will hold a minority equity stake in that spinout.
• KCNT1+ epilepsy affects roughly 2,500 people in the US, many experiencing dozens to hundreds of seizures daily, with onset often in infancy that blocks basic milestones like walking or speaking.
• Actio had raised over $110 million since its 2021 founding from backers including Deerfield Management, Regeneron Ventures, Canaan, and Droia Ventures.
• This is Jazz's second acquisition in as many years and builds on its 2025 licensing deal with Saniona, following its 2021 purchase of GW Pharma, whose Epidiolex epilepsy drug topped $1 billion in annual revenue last year.
• The deal shows mid-size biopharmas can be consistent acquirers of clinical-stage rare-disease assets, deepening pipelines in narrow, high-unmet-need indications that larger pharma often overlooks.